Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AAREYDRUGS.NS Stock Summary
Top 10 Correlated ETFs
AAREYDRUGS.NS
In the News
AAREYDRUGS.NS Financial details
Company Rating
Neutral
Market Cap
1.19B
Income
37.75M
Revenue
3.43B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
27 May 2024
P/E
65.16
Forward P/E
-
PEG
-14.53
P/S
0.47
P/B
1.3
P/C
-
P/FCF
-
Quick Ratio
1.34
Current Ratio
1.98
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
1.5
EPS next Y
-
EPS next Q
-
EPS this Y
-45.22%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-11.85%
Revenue last 5Y
3.15%
Revenue Q/Q
32.24%
EPS Q/Q
141.94%
-
-
-
-
SMA20
-10.6%
SMA50
-27.41%
SMA100
2.54%
Inst Own
-
Inst Trans
-
ROA
1%
ROE
4%
ROC
0.06%
Gross Margin
3%
Oper. Margin
2%
Profit Margin
1%
Payout
-
Shs Outstand
25.38M
Shs Float
9.92M
-
-
-
-
Target Price
-
52W Range
22.0-68.0
52W High
-33.82%
52W Low
+104.55%
RSI
50.28
Rel Volume
0.1
Avg Volume
113.54K
Volume
11.22K
Perf Week
13.92%
Perf Month
-5.16%
Perf Quarter
-3.54%
Perf Half Y
-7.31%
-
-
-
-
Beta
0.905
-
-
Volatility
1.58%, 3.54%
Prev Close
2.27%
Price
45
Change
-0.44%
AAREYDRUGS.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 151.68 | 128.33 | 148.77 | 204.2 | 163.19 | |
Net income per share | 2.8 | 2.48 | 2.79 | 2.72 | 1.49 | |
Operating cash flow per share | 0.29 | 1.22 | 2.34 | -1.87 | -0.5 | |
Free cash flow per share | -0.23 | 0.83 | 1.11 | -2.78 | -0.92 | |
Cash per share | 0.16 | 0.21 | 0.28 | 3.2 | 0.44 | |
Book value per share | 37.01 | 39.49 | 42.28 | 47.2 | 46.25 | |
Tangible book value per share | 37.01 | 39.49 | 42.28 | 47.2 | 46.25 | |
Share holders equity per share | 37.01 | 39.49 | 42.28 | 47.2 | 46.25 | |
Interest debt per share | 7.82 | 8.37 | 8.7 | 8.06 | 15.99 | |
Market cap | 1.01B | 1.01B | 1.01B | 997.91M | 609.24M | |
Enterprise value | 1.17B | 1.19B | 1.19B | 1.14B | 979.36M | |
P/E ratio | 15.5 | 17.5 | 15.56 | 15.22 | 16.16 | |
Price to sales ratio | 0.29 | 0.34 | 0.29 | 0.2 | 0.15 | |
POCF ratio | 147.19 | 35.48 | 18.51 | -22.21 | -47.56 | |
PFCF ratio | -187.94 | 52.29 | 39.02 | -14.91 | -26.2 | |
P/B Ratio | 1.17 | 1.1 | 1.03 | 0.88 | 0.52 | |
PTB ratio | 1.17 | 1.1 | 1.03 | 0.88 | 0.52 | |
EV to sales | 0.33 | 0.4 | 0.34 | 0.23 | 0.24 | |
Enterprise value over EBITDA | 9.66 | 12.07 | 10.28 | 8.15 | 9.37 | |
EV to operating cash flow | 170.14 | 41.57 | 21.68 | -25.32 | -76.45 | |
EV to free cash flow | -217.25 | 61.27 | 45.71 | -16.99 | -42.12 | |
Earnings yield | 0.06 | 0.06 | 0.06 | 0.07 | 0.06 | |
Free cash flow yield | -0.01 | 0.02 | 0.03 | -0.07 | -0.04 | |
Debt to equity | 0.19 | 0.19 | 0.18 | 0.15 | 0.32 | |
Debt to assets | 0.11 | 0.09 | 0.08 | 0.07 | 0.13 | |
Net debt to EBITDA | 1.3 | 1.77 | 1.51 | 1 | 3.54 | |
Current ratio | 2.31 | 1.81 | 1.65 | 1.74 | 1.61 | |
Interest coverage | 4.26 | 3.77 | 3.55 | 5.24 | 2.33 | |
Income quality | 0.08 | 0.39 | 0.66 | -0.45 | -0.21 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.04 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | -1.78 | -0.32 | -0.53 | 0.49 | 0.81 | |
Capex to revenue | 0 | 0 | -0.01 | 0 | 0 | |
Capex to depreciation | -1.22 | -1.03 | -3.13 | -1.11 | -0.66 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 48.27 | 46.92 | 51.48 | 53.77 | 39.32 | |
ROIC | 0.06 | 0.05 | 0.06 | 0.05 | 0.03 | |
Return on tangible assets | 0.04 | 0.03 | 0.03 | 0.03 | 0.01 | |
Graham Net | 15.1 | 12.88 | 10.75 | 17.57 | -3.66 | |
Working capital | 753.6M | 810.66M | 857.66M | 962.47M | 1.02B | |
Tangible asset value | 865.53M | 923.46M | 988.6M | 1.14B | 1.17B | |
Net current asset value | 738.3M | 796.07M | 842.02M | 947.92M | 966.95M | |
Invested capital | 0.19 | 0.19 | 0.18 | 0.15 | 0.32 | |
Average receivables | 1.25B | 1.38B | 1.82B | 2.06B | 2.06B | |
Average payables | 574.29M | 575.14M | 940.45M | 1.1B | 1.18B | |
Average inventory | 180.13M | 191.23M | 177.28M | 160.72M | 212.52M | |
Days sales outstanding | 114.52 | 199.22 | 209.04 | 157.69 | 175.16 | |
Days payables outstanding | 39.91 | 97.8 | 119.23 | 84.79 | 115.08 | |
Days of inventory on hand | 22.75 | 21.38 | 19.95 | 10.58 | 26.05 | |
Receivables turnover | 3.19 | 1.83 | 1.75 | 2.31 | 2.08 | |
Payables turnover | 9.15 | 3.73 | 3.06 | 4.3 | 3.17 | |
Inventory turnover | 16.05 | 17.07 | 18.3 | 34.5 | 14.01 | |
ROE | 0.08 | 0.06 | 0.07 | 0.06 | 0.03 | |
Capex per share | -0.53 | -0.39 | -1.23 | -0.91 | -0.41 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 24.61 | 62.31 | 20.07 | 22.78 | 30.13 | |
Net income per share | 0.19 | 0.14 | 0.29 | 0.31 | 0.75 | |
Operating cash flow per share | 0.43 | 0.16 | 0.33 | 0.32 | 0.37 | |
Free cash flow per share | 0.43 | 0.16 | 0.33 | 0.32 | 0.37 | |
Cash per share | 0.05 | 0.44 | 0.44 | 2.94 | 0 | |
Book value per share | 45.92 | 46.25 | 46.25 | 46.85 | 0 | |
Tangible book value per share | 0 | 46.25 | 0 | 46.85 | 0 | |
Share holders equity per share | 45.92 | 46.25 | 46.25 | 46.85 | 0 | |
Interest debt per share | 0.28 | 15.26 | 0.35 | 15.22 | 0.42 | |
Market cap | 981.12M | 609.23M | 873.23M | 1.23B | 1.54B | |
Enterprise value | 982.36M | 979.36M | 884.47M | 1.59B | 1.54B | |
P/E ratio | 49.6 | 42.64 | 30.12 | 39.22 | 20.17 | |
Price to sales ratio | 1.57 | 0.39 | 1.71 | 2.13 | 2.01 | |
POCF ratio | 89 | 152.23 | 104.93 | 150.18 | 163.09 | |
PFCF ratio | 89 | 152.23 | 104.93 | 150.18 | 163.09 | |
P/B Ratio | 0.84 | 0.52 | 0.74 | 1.04 | 0 | |
PTB ratio | 0.84 | 0.52 | 0.74 | 1.04 | 0 | |
EV to sales | 1.57 | 0.62 | 1.74 | 2.75 | 2.01 | |
Enterprise value over EBITDA | 48.94 | 29.12 | 43.45 | 59.38 | 56.95 | |
EV to operating cash flow | 89.11 | 244.72 | 106.28 | 194.34 | 163.09 | |
EV to free cash flow | 89.11 | 244.72 | 106.28 | 194.34 | 163.09 | |
Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Free cash flow yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Debt to equity | 0 | 0.32 | 0 | 0.31 | 0 | |
Debt to assets | 0 | 0.13 | 0 | 0.16 | 0 | |
Net debt to EBITDA | 0.06 | 11.01 | 0.55 | 13.49 | 0 | |
Current ratio | 0 | 1.61 | 0 | 1.98 | 0 | |
Interest coverage | 2.05 | 3.11 | 1.03 | 1.8 | 2.11 | |
Income quality | 2.23 | 1.12 | 1.15 | 1.04 | 0.49 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 14.19 | 12.1 | 17.24 | 18.05 | 0 | |
ROIC | 0.01 | 0 | 0 | 0.01 | 0 | |
Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
Graham Net | 0.05 | -3.66 | 0.44 | 3.16 | 0 | |
Working capital | 1.24M | 1.02B | 11.24M | 1.08B | 0 | |
Tangible asset value | 0 | 1.17B | 0 | 1.19B | 0 | |
Net current asset value | 1.24M | 966.95M | 11.24M | 1.03B | 0 | |
Invested capital | 0 | 0.32 | 0 | 0.31 | 0 | |
Average receivables | 668.76M | 993.96M | 993.96M | 696.35M | 696.35M | |
Average payables | 405.6M | 636.65M | 636.65M | 305.48M | 305.48M | |
Average inventory | 102.52M | 144.1M | 144.1M | 111.86M | 111.86M | |
Days sales outstanding | 0 | 113.11 | 0 | 216.74 | 0 | |
Days payables outstanding | 0 | 72.62 | 0 | 99.67 | 0 | |
Days of inventory on hand | 0 | 16.44 | 0 | 36.5 | 0 | |
Receivables turnover | 0 | 0.8 | 0 | 0.42 | 0 | |
Payables turnover | 0 | 1.24 | 0 | 0.9 | 0 | |
Inventory turnover | 0 | 5.48 | 0 | 2.47 | 0 | |
ROE | 0 | 0 | 0.01 | 0.01 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
AAREYDRUGS.NS Frequently Asked Questions
What is Aarey Drugs & Pharmaceuticals Limited stock symbol ?
Aarey Drugs & Pharmaceuticals Limited is a IN stock and trading under the symbol AAREYDRUGS.NS
What is Aarey Drugs & Pharmaceuticals Limited stock quote today ?
Aarey Drugs & Pharmaceuticals Limited stock price is $45 today.
Is Aarey Drugs & Pharmaceuticals Limited stock public?
Yes, Aarey Drugs & Pharmaceuticals Limited is a publicly traded company.